Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How would you manage severe agranulocytosis in an elderly pt with CMML - 0, low risk by Mayo model?
Related Questions
What hemoglobin level prompts you to start erythropoietin in a patient with low-risk MDS?
Do you use lenalidomide for patients with MDS with 5q- without other cytogenetic abnormalities but with one or more mutations on NGS?
Are you now using luspatercept as your first choice for anemia management in patients with low-risk MDS otherwise appropriate for EPO initiation, regardless of presence of SF3B1 or ringed sideroblasts?
What are common indications for ordering NGS of peripheral blood?
How do you approach a patient with CMML requiring platelet transfusions?
Would you still recommend bone marrow biopsy in an elderly non-transplant eligible patient with mild cytopenias if NGS from peripheral blood indicates MDS mutations?
How do you treat an MDS patient who presents with significant cytopenias who is not a candidate for lenalidomide or luspatercept? How do you initiate an HMA when they are severely neutropenic?
Is there an advantage to early therapy with hypomethylating agents for high/very high risk patients with MDS who are not transplant candidates and have only mild cytopenias?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
